GlassScriptPhysician profile
Danielle Rogers
NPI 1942023817
$2,459.89
in general payments reported to CMS, 2019-2025
27 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.17 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.26 | 2025 | |
| Novo Nordisk INC | $347.46 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $271.73 | 2025 | Airsupra, Breztri, Farxiga |
| Boston Scientific Corporation | $181.36 | 2025 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $148.77 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $112.34 | 2025 | Invega Sustenna |
| Amgen INC. | $88.17 | 2025 | Evenity, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $84.48 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $80.81 | 2025 | Rexulti |
| Lundbeck LLC | $79.71 | 2025 | Rexulti |
| Medtronic, INC. | $77.31 | 2025 | Minimed 780g, Prestige LP Cervical Disc System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.75 | 2025 | Caplyta |
| Pfizer INC. | $68.58 | 2025 | |
| Exact Sciences Corporation | $55.17 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $46.70 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $40.76 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $38.95 | 2025 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $34.28 | 2025 | Belbuca |
| Lilly USA, LLC | $34.16 | 2025 | Jardiance, Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $33.72 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.69 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $33.43 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $31.72 | 2025 | Zoryve |
| Astellas Pharma US INC | $20.20 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $19.20 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $15.30 | 2025 | Symbravo |
| Edwards Lifesciences Corporation | $13.88 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.